The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24-months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity. Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.
The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:
- Marat Fudim -- Consultant Roles: Axon Therapies, Alleviant, CVRX, Impulse Dynamics, Abbott, Endotronix.
- Shelley Hall -- Consultant Roles: Device Manufacturer: Abbott, CVRX. Diagnostic Labs: Care DX, Natera
- Liviu Klein -- Consultant Roles: Device Manufacturers/Disbributors: Abbott, Boston Scientific, Edwards, Medtronic
- Daniel Bensimhon -- Advisory Board, Equity: Sensible Medical. Consulting: Caption Health. Consulting/Stock Ownership: ScPharmaceuticals. Advisory Boards/Stock Options: Corstasis, AquaPass. Founder/Equity: Ventricle Health. Speaker Bureau Relationships: Astrazenca, Bayer, Boehringer Ingelheim/Lilly, Janssen, Pfizer, ScPharmaceuticals, Merck
- Andrew Sauer -- Research Funding from Bayer, National Lead Investigator, Scientific Oversight with ARO REDEFINE-HF, CONFIRMATION-HF, FINALITY-HF (MOONRAKER PROGRAM) Senior Scientific Advisor, Acorai, CAPTURE-HF study, POC Hemodynamics Senior Scientific Advisor, General Prognostics, TRIBE-2 study and program National Lead Investigator and Study Medical Monitor, CSL-Vifor CARE-HK Registry Steering Committee, Rivus, HuMAIN Phase II study of HU6 Metabolic Accelerator in HFpEF Steering Committee, Boston Scientific, LUX-DX-TRENDS Heart Logic study, Medical Optimization Committee, TRILUMINATE Study, Abbott; Advising for Amgen, Phase III Clinical Trial Program: Obesity in HFpEF Pharmacotherapy; Advising for 35Pharma, Phase I/II Clinical Trial Program: Obesity in HFpEF Pharmacotherapy; Advising for Regeneron, Phase II Clinical Trial Program: Obesity in HFpEF Pharmacotherapy; Senior Advisor: I own stock in ISHI, a privately owned digital health services company. Senior Advisor: I own stock in Pulsli, a privately owned digital health technology company; Advising / Research Funding: Abbott, Impulse Dynamics, Pfizer, Astra Zeneca, CSL-Vifor, Edwards.
Off-Label Disclosure
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.